Recruiting
Phase 2

Cannabidiol

Sponsor:

Kevin Boehnke

Code:

NCT06213233

Conditions

Pain, Chronic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Placebo

Cannabidiol

Study Details

Brief summary:

This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain.

Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period.

The study hypotheses:

\- CBD would improve overall pain symptoms compared to placebo

Conditions

Pain, Chronic

Study ID

NCT06213233

Start date

Feb 12, 2024

Status verified date

May, 2026

Completion date

Dec, 2028

Anticipated

Primary completion date

Dec, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
  • Armed Services Veteran
  • All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
  • Reports moderate to severe chronic pain defined by protocol
  • Currently using or interested in using cannabis for pain management
  • Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
  • Individuals of reproductive potential must agree to use acceptable birth control per protocol
  • Participants must also agree not to donate sperm or eggs during study drug administration
  • Willingness to attend all study visits (may be done virtually)
  • Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
  • Willingness to wear Fitbit or other similar sensor for passive-data collection
  • Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use

Exclusion Criteria:

  • Not an Armed Services Veteran
  • Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
  • Participant reports pregnancy or are nursing
  • Planning to move out of a state with legal recreational marijuana use during course of study
  • Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
  • Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
  • Participation in any other clinical trials over the course of this study
  • Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
  • Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
  • Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
  • Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)
  • Current valproate and clobazam use per self-report or medical records
  • Self-reported allergies to sesame oil or cannabis/cannabinoids

Study Design

Enrollment

468 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: Placebo

experimental: Cannabidiol

Interventions

Placebo

Participant will take placebo days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

Cannabidiol

Participant will take Epidiolex days 1-28 during study treatment. Given the pragmatic design, participants will be instructed to take the study drug whenever participants wish, with suggested starting dosing of 0.2 milliliter (mL) in the morning and 0.2mL in the evening (up to 1.2mL per day).

Primary outcome measure

  • Global impression of change (PGIC) between groups at end of treatment (Day 28) [ Time Frame: Day 28 ]

Central Contacts and Locations

Central contacts

Catherine Klida

734-998-8010crklida@med.umich.edu

Locations

University of Michigan

Recruiting

Ann Arbor, Michigan, United States, 48109

Contacts

Catherine Klida

734-998-8010crklida@med.umich.edu

Principal Investigator:

Kevin Boehnke, PhD

More Information

Sponsor

Kevin Boehnke

Last update posted

Jun 1, 2026

Last verified

May, 2026

Keywords

  • Cannabidiol (CBD)
  • Veterans
  • Surveys
  • Fitbit wearable

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Kevin Boehnke on 2026-06-01.